The Neuropathology of Neurodegeneration with Brain Iron Accumulation

International Review of Neurobiology

Volumn 110, Issue , 2013, Pages 165-194

  Kruer, Michael C ^a  

^a Sanford Children's Hospital   (United States)

Author keywords

Dystonia; Iron deposition; Neurodegeneration; Neuropathology; Parkinsonism

Indexed keywords

CERULOPLASMIN; SYNUCLEIN; TAU PROTEIN;

ACERULOPLASMINEMIA; ARTICLE; ATP13A2 GENE; BETA PROPELLER PROTEIN ASSOCIATED NEURODEGENERATION; C19ORF12 GENE; CLINICAL FEATURE; DISEASE ASSOCIATION; FA2H GENE; GENE; GENE MUTATION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; IRON OVERLOAD; IRON STORAGE; KUFOR RAKEB SYNDROME; LEWY BODY; MITOCHONDRIAL MEMBRANE PROTEIN ASSOCIATED NEURODEGENERATION; MOLECULAR PATHOLOGY; NERVE DEGENERATION; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; NEUROFERRITINOPATHY; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; PANK2 GENE; PHOSPHOLIPASE ASSOCIATED NEURODEGENERATION; PLA2G6 GENE; PRIORITY JOURNAL; TUMOR SPHEROID; WDR45 GENE;

DYSTONIA; IRON DEPOSITION; NEURODEGENERATION; NEUROPATHOLOGY; PARKINSONISM;

BRAIN; HUMANS; IRON METABOLISM DISORDERS; NEUROAXONAL DYSTROPHIES;

EID: 84887227601     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-410502-7.00009-0     Document Type: Chapter

References (36)

1. Baraibar M.A., Muhoberac B.B., Garringer H.J., Hurley T.D., Vidal R. Unraveling of the E-helices and disruption of 4-fold pores are associated with iron mishandling in a mutant ferritin causing neurodegeneration. Journal of Biological Chemistry 2010, 285(3):1950-1956.
2. Bras J., Verloes A., Schneider S.A., Mole S.E., Guerreiro R.J. Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis. Human Molecular Genetics 2012, 21(12):2646-2650.
3. Brüggemann N., Hagenah J., Reetz K., Schmidt A., Kasten M., Buchmann I., et al. Recessively inherited parkinsonism: Effect of ATP13A2 mutations on the clinical and neuroimaging phenotype. Archives of Neurology 2010, 67(11):1357-1363.
4. Crosiers D., Ceulemans B., Meeus B., Nuytemans K., Pals P., Van Broeckhoven C., et al. Juvenile dystonia-parkinsonism and dementia caused by a novel ATP13A2 frameshift mutation. Parkinsonism & Related Disorders 2011, 17(2):135-138.
5. Eidelberg D., Sotrel A., Joachim C., Selkoe D., Forman A., Pendlebury W.W., et al. Adult onset Hallervorden-Spatz disease with neurofibrillary pathology. A discrete clinicopathological entity. Brain 1987, 110(Pt 4):993-1013.
6. Gregory A., Westaway S.K., Holm I.E., Kotzbauer P.T., Hogarth P., Sonek S., et al. Neurodegeneration associated with genetic defects in phospholipase A(2). Neurology 2008, 71(18):1402-1409.
7. Hartig M.B., Iuso A., Haack T., Kmiec T., Jurkiewicz E., Heim K., et al. Absence of an orphan mitochondrial protein, c19orf12, causes a distinct clinical subtype of neurodegeneration with brain iron accumulation. American Journal of Human Genetics 2011, 89(4):543-550.
8. Hattori A., Miyajima H., Tomosugi N., Tatsumi Y., Hayashi H., Wakusawa S. Clinicopathological study of Japanese patients with genetic iron overload syndromes. Pathology International 2012, 62(9):612-618.
9. Hautot D., Pankhurst Q.A., Morris C.M., Curtis A., Burn J., Dobson J. Preliminary observation of elevated levels of nanocrystalline iron oxide in the basal ganglia of neuroferritinopathy patients. Biochimica et Biophysica Acta 2007, 1772(1):21-25.
10. Hayflick S.J., Hartman M., Coryell J., Gitschier J., Rowley H. Brain MRI in neurodegeneration with brain iron accumulation with and without PANK2 mutations. American Journal of Neuroradiology 2006, 27(6):1230-1233.
11. Hogarth P., Gregory A., Kruer M.C., Sanford L., Wagoner W., Natowicz M.R., et al. New NBIA subtype: Genetic, clinical, pathologic, and radiographic features of MPAN. Neurology 2013, 80(3):268-275.
12. Kaneko K., Hineno A., Yoshida K., Ohara S., Morita H., Ikeda S. Extensive brain pathology in a patient with aceruloplasminemia with a prolonged duration of illness. Human Pathology 2012, 43(3):451-456.
13. Kaneko K., Yoshida K., Arima K., Ohara S., Miyajima H., Kato T., et al. Astrocytic deformity and globular structures are characteristic of the brains of patients with aceruloplasminemia. Journal of Neuropathology and Experimental Neurology 2002, 61(12):1069-1077.
14. Kruer M.C., Hiken M., Gregory A., Malandrini A., Clark D., Hogarth P., et al. Novel histopathologic findings in molecularly-confirmed pantothenate kinase-associated neurodegeneration. Brain 2011, 134(Pt 4):947-958.
15. Kuo Y.M., Duncan J.L., Westaway S.K., Yang H., Nune G., Xu E.Y., et al. Deficiency of pantothenate kinase 2 (Pank2) in mice leads to retinal degeneration and azoospermia. Human Molecular Genetics 2005, 14(1):49-57.
16. Kuo Y.M., Hayflick S.J., Gitschier J. Deprivation of pantothenic acid elicits a movement disorder and azoospermia in a mouse model of pantothenate kinase-associated neurodegeneration. Journal of Inherited Metabolic Disease 2007, 30(3):310-317.
17. Li A., Paudel R., Johnson R., Courtney R., Lees A.J., Holton J.L., et al. Pantothenate kinase-associated neurodegeneration is not a synucleinopathy. Neuropathology and Applied Neurobiology 2012, (Epub ahead of print).
18. Malandrini A., Bonuccelli U., Parrotta E., Ceravolo R., Berti G., Guazzi G.C. Myopathic involvement in two cases of Hallervorden-Spatz disease. Brain & Development 1995, 17(4):286-290.
19. Malandrini A., Cavallaro T., Fabrizi G.M., Berti G., Salvestroni R., Salvadori C., et al. Ultrastructure and immunoreactivity of dystrophic axons indicate a different pathogenesis of Hallervorden-Spatz disease and infantile neuroaxonal dystrophy. Virchows Archiv 1995, 427(4):415-421.
20. Malandrini A., Rubegni A., Battisti C., Berti G., Federico A. Electron-dense lamellated inclusions in 2 siblings with Kufor-Rakeb syndrome. Movement Disorders 2013, (Epub ahead of print).
21. Malik I., Turk J., Mancuso D.J., Montier L., Wohltmann M., Wozniak D.F., et al. Disrupted membrane homeostasis and accumulation of ubiquitinated proteins in a mouse model of infantile neuroaxonal dystrophy caused by PLA2G6 mutations. American Journal of Pathology 2008, 172(2):406-416.
22. Mancuso M., Davidzon G., Kurlan R.M., Tawil R., Bonilla E., Di Mauro S., et al. Hereditary ferritinopathy: A novel mutation, its cellular pathology, and pathogenetic insights. Journal of Neuropathology and Experimental Neurology 2005, 64(4):280-294.
23. Oide T., Yoshida K., Kaneko K., Ohta M., Arima K. Iron overload and antioxidative role of perivascular astrocytes in aceruloplasminemia. Neuropathology and Applied Neurobiology 2006, 32(2):170-176.
24. Paisan-Ruiz C., Bhatia K.P., Li A., Hernandez D., Davis M., Wood N.W., et al. Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Annals of Neurology 2009, 65(1):19-23.
25. Paisán-Ruiz C., Guevara R., Federoff M., Hanagasi H., Sina F., Elahi E., et al. Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations. Movement Disorders 2010, 25(12):1791-1800.
26. Paisán-Ruiz C., Li A., Schneider S.A., Holton J.L., Johnson R., Kidd D., et al. Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations. Neurobiology of Aging 2012, 33(4):814-823.
27. Potter K.A., Kern M.J., Fullbright G., Bielawski J., Scherer S.S., Yum S.W., et al. Central nervous system dysfunction in a mouse model of FA2H deficiency. Glia 2011, 59(7):1009-1021.
28. Santoro L., Breedveld G.J., Manganelli F., Iodice R., Pisciotta C., Nolano M., et al. Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability. Neurogenetics 2011, 12(1):33-39.
29. Schneider S.A., Paisan-Ruiz C., Quinn N.P., Lees A.J., Houlden H., Hardy J., et al. ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. Movement Disorders 2010, 25(8):979-984.
30. Schneider S.A., Bhatia K.P. Excess iron harms the brain: The syndromes of neurodegeneration with brain iron accumulation (NBIA). Journal of Neural Transmission 2013, 120(4):695-703.
31. Schultheis P.J., Fleming S.M., Clippinger A.K., Lewis J., Tsunemi T., Giasson B., et al. Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited α-synuclein accumulation and age-dependent sensorimotor deficits. Human Molecular Genetics 2013, 22(10):2067-2082.
32. Shevell M. Racial hygiene, active euthanasia, and Julius Hallervorden. Neurology 1992, 42(11):2214-2219.
33. Wada H., Yasuda T., Miura I., Watabe K., Sawa C., Kamijuku H., et al. Establishment of an improved mouse model for infantile neuroaxonal dystrophy that shows early disease onset and bears a point mutation in Pla2g6. American Journal of Pathology 2009, 175(6):2257-2263.
34. Wolkow N., Song Y., Wu T.D., Qian J., Guerquin-Kern J.L., Dunaief J.L. Aceruloplasminemia: Retinal histopathologic manifestations and iron-mediated melanosome degradation. Archives of Ophthalmology 2011, 129(11):1466-1474.
35. Zhou B., Westaway S.K., Levinson B., Johnson M.A., Gitschier J., Hayflick S.J. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nature Genetics 2001, 28(4):345-349.
36. Zöller I., Meixner M., Hartmann D., Büssow H., Meyer R., Gieselmann V., et al. Absence of 2-hydroxylated sphingolipids is compatible with normal neural development but causes late-onset axon and myelin sheath degeneration. Journal of Neuroscience 2008, 28(39):9741-9754.